Report of Foreign Issuer (6-k)
September 26 2016 - 1:33PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 26 September 2016
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc (the
'
Company
')
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr R G Connor
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the
transaction
|
Following the vesting on 23 September 2016 of 50% of an award made
on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award
Plan, Mr R Connor will receive a cash payment of £237,076.13
less applicable tax withholding in respect of 14,376.963 notional
Ordinary Shares.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.49
|
14,376.963
notional Ordinary Shares.
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2016-09-23
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr S A Hussain
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the
transaction
|
Following the vesting on 23 September 2016 of 50% of an award made
on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award
Plan, Mr Hussain will receive a cash payment of £296,345.16
less applicable tax withholding in respect of 17,971.204 notional
Ordinary Shares.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.49
|
17,971.204
notional Ordinary Shares
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2016-09-23
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr D S Redfern
|
b)
|
Position/status
|
Chief Strategy Officer
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the
transaction
|
Following the vesting on 23 September 2016 of 50% of an award made
on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award
Plan, Mr Redfern will receive a cash payment of £237,076.13
less applicable tax withholding in respect of 14,376.963 notional
Ordinary Shares.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.49
|
14,376.963
notional Ordinary Shares
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2016-09-23
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms C Thomas
|
b)
|
Position/status
|
SVP, Human Resources
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the
transaction
|
Following the vesting on 23 September 2016 of 50% of an award made
on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award
Plan, Ms Thomas will receive a cash payment of £237,076.13
less applicable tax withholding in respect of 14,376.963 notional
Ordinary Shares.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.49
|
14,376.963
notional Ordinary Shares
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2016-09-23
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr P J T Vallance
|
b)
|
Position/status
|
President, Pharmaceuticals
Research & Development
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the
transaction
|
Following the vesting on 23 September 2016 of 50% of an award made
on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award
Plan, Mr Vallance will receive a cash payment of £296,345.16
less applicable tax withholding in respect of 17,971.204 notional
Ordinary Shares.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.49
|
17,971.204
notional Ordinary Shares
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2016-09-23
|
f)
|
Place
of the transaction
|
n/a
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: September
26, 2016
By: VICTORIA
WHYTE
----------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GlaxoSmithKline plc
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024